Exelixis, Inc.
Every calculator, already run for EXEL
Open the full toolkit →You have the numbers on EXEL. Get the argument.
A written report on which of these readings actually decide the outcome for Exelixis, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
19 analysts covering EXELAnalyst Price Target Disagreement for Exelixis, Inc.
Wall Street's bull case implies +13% from the current price; the bear case implies -30%. A 43% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for EXEL
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Exelixis, Inc.
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an or…
EXEL — frequently asked
Is EXEL a buy right now?
Wall Street's consensus rating on Exelixis, Inc. is Buy across 19 analysts, with a mean price target of $53.69 (-8% vs. the current $58.16). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is EXEL overvalued?
EXEL trades at 18.3x trailing earnings, against a DCF fair value of $104 per share. The current price implies -1% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is EXEL's next earnings date?
Exelixis, Inc. is next scheduled to report earnings around Oct 27, 2026. A full EXEL research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Exelixis, Inc.?
Analysts covering Exelixis, Inc. (EXEL) range from a bear-case target of $41.00 to a bull-case high of $66.00, with a mean consensus target of $53.69 across 16 analysts. The spread of $25.00 (43% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Exelixis, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Exelixis, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full EXEL research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Exelixis, Inc., in minutes. 3 free reports included with every account — no credit card required.